Annotation Detail for TPH2
Basic Information
Top
Pathway ID | Pathway Name |
---|
PWY-6030 | serotonin and melatonin biosynthesis |
Pathway ID | Pathway Name |
---|
P04371 | 5-Hydroxytryptamine biosynthesis |
Desease Name |
---|
personality traits |
ADHD |
response inhibition |
PSYCH |
bipolar disorder unipolar disorder |
bipolar disorder depressive disorder, major |
attention-deficit hyperactivity disorder |
suicide |
bipolar disorder suicide |
attention deficit hyperactivity disorder |
impulsivity |
depression |
panic disorder |
Autism |
Desease Name |
---|
Unipolar depression, susceptibility to |
Attention deficit-hyperactivity disorder, susceptibility to, 7 |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of TPH2 mRNA | affects expression | 16483693
|
D005473 |
Fluoxetine |
Fluoxetine results in increased expression of TPH2 mRNA | increases expression | 11901216
|
D018021 |
Lithium Chloride |
Lithium Chloride results in decreased expression of TPH2 mRNA | decreases expression | 19840776
|
D018021 |
Lithium Chloride |
Lithium Chloride results in decreased expression of TPH2 protein | decreases expression | 19840776
|
D008550 |
Melatonin |
TPH2 protein affects the chemical synthesis of Melatonin | affects chemical synthesis | 15281067
|
C063509 |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sertraline results in increased expression of TPH2 mRNA] | decreases reaction|increases expression | 11901216
|
D020280 |
Sertraline |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sertraline results in increased expression of TPH2 mRNA] | decreases reaction|increases expression | 11901216
|
D020280 |
Sertraline |
Sertraline results in increased activity of TPH2 protein | increases activity | 11901216
|
D020280 |
Sertraline |
Sertraline results in increased expression of TPH2 mRNA | increases expression | 11901216
|
D020280 |
Sertraline |
Sertraline results in increased expression of TPH2 protein | increases expression | 11901216
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
4.02 | 18287403 |
MESH:D000236 |
Adenoma |
|
Melatonin |
4.53 | 17195641 |
MESH:D001008 |
Anxiety Disorders |
|
Fluoxetine |
10.75 | 18083778 |
MESH:D001008 |
Anxiety Disorders |
|
Sertraline |
10.75 | 18822694 |
MESH:D001289 |
Attention Deficit Disorder with Hyperactivity |
marker/mechanism |
|
| |
MESH:D001321 |
Autistic Disorder |
marker/mechanism |
|
| 15768392 |
MESH:D001321 |
Autistic Disorder |
|
Fluoxetine |
2.81 | 18775368 19232924 |
MESH:D001321 |
Autistic Disorder |
|
Melatonin |
2.81 | 16897403 16919138 |
MESH:D001321 |
Autistic Disorder |
|
Sertraline |
2.81 | 18775368 |
MESH:D002252 |
Carbon Tetrachloride Poisoning |
|
Melatonin |
5.73 | 15700767 |
MESH:D003866 |
Depressive Disorder |
|
Fluoxetine |
9.53 | 15014590 |
MESH:D003866 |
Depressive Disorder |
|
Sertraline |
9.53 | 15014590 20305041 18822694 |
MESH:D003865 |
Depressive Disorder, Major |
marker/mechanism |
|
| |
MESH:D003865 |
Depressive Disorder, Major |
|
Sertraline |
5.65 | 16968574 |
MESH:D004487 |
Edema |
|
Fluoxetine |
4.69 | 12798668 |
MESH:D019584 |
Hot Flashes |
|
Fluoxetine |
5.83 | 14716179 |
MESH:D006816 |
Huntington Disease |
|
Sertraline |
6.44 | 18403212 |
MESH:D006869 |
Hydronephrosis |
|
Lithium Chloride |
6.54 | 19797860 |
MESH:D007249 |
Inflammation |
|
Fluoxetine |
3.99 | 12798668 |
MESH:D008064 |
Lipidoses |
|
Fluoxetine |
9.68 | 15342952 17567588 |
MESH:D008064 |
Lipidoses |
|
Sertraline |
9.68 | 17567588 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Melatonin |
3.28 | 15925388 16703270 15298665 |
MESH:D008175 |
Lung Neoplasms |
|
Melatonin |
3.28 | 17195641 |
MESH:D008180 |
Lupus Erythematosus, Systemic |
|
Melatonin |
3.98 | 16373423 |
MESH:D001523 |
Mental Disorders |
|
Fluoxetine |
10.49 | 16856516 |
MESH:D001523 |
Mental Disorders |
|
Sertraline |
10.49 | 16856516 |
MESH:D009207 |
Myoclonus |
|
Fluoxetine |
6.34 | 8041377 |
MESH:D009336 |
Necrosis |
|
Melatonin |
5.93 | 12195237 |
MESH:D009771 |
Obsessive-Compulsive Disorder |
|
Fluoxetine |
5.77 | 20418887 |
MESH:D010146 |
Pain |
|
Fluoxetine |
4.60 | 12798668 |
MESH:D020734 |
Parkinsonian Disorders |
|
Melatonin |
5.34 | 15574749 |
MESH:D010538 |
Peritonitis |
|
Melatonin |
5.73 | 15707874 |
MESH:D020774 |
Pick Disease of the Brain |
|
Fluoxetine |
6.42 | 8041377 |
MESH:D011141 |
Polyuria |
|
Lithium Chloride |
6.46 | 19692487 |
MESH:D020230 |
Serotonin Syndrome |
|
Fluoxetine |
6.42 | 8704074 |
MESH:D012893 |
Sleep Disorders |
|
Melatonin |
5.93 | 16919138 16897403 18182647 |
MESH:D020178 |
Sleep Disorders, Circadian Rhythm |
|
Melatonin |
7.15 | 18078449 19452292 |
MESH:D007319 |
Sleep Initiation and Maintenance Disorders |
|
Melatonin |
5.77 | 18078449 |
MESH:D013276 |
Stomach Ulcer |
|
Melatonin |
4.82 | 11523592 12500499 16150113 |
Drugbank ID |
Action |
Drug Name |
Description |
---|
DB00150 |
- |
L-Tryptophan |
Dietary supplement;Micronutrient;Essential Amino Acids;Antidepressive Agents, Second-Generation |